Giredestrant: The Core Catalyst

The upgrade is anchored on a dramatic revaluation of giredestrant, Roche's investigational oral selective estrogen receptor degrader (SERD) for ER+/HER2- breast cancer.

Expected FDA Decisions

Morgan Stanley analysts expect two U.S. approval decisions for giredestrant in late 2026 :

• lidERA study in adjuvant ER+/HER2-negative breast cancer — PDUFA date of November 30, 2026 .
• evERA study in post-CDK4/6 metastatic breast cancer — PDUFA date of December 18, 2026 .

The FDA accepted the New Drug Application (NDA) under Priority Review in June 2026 for the adjuvant indication . Giredestrant is the only oral SERD to show superior invasive disease-free survival in the adjuvant setting, marking the first significant endocrine therapy advance in over 20 years .

First-Year Sales Forecast

Morgan Stanley projects first-year U.S. giredestrant sales of roughly CHF 660 million (approximately $800 million), with upside to $1–1.2 billion depending on conversion of CDK4/6-intolerant patients . This reflects a faster launch trajectory and larger market capture than the bank previously modeled .

Peak Sales Potential

Roche has cited at least $14 billion in peak sales potential from the early-stage breast cancer SERD market alone, with a total addressable market of at least $20 billion for the drug class . Morningstar, which raised its fair value estimate for Roche to CHF 381 in April 2026, now assumes more than CHF 4 billion in giredestrant sales by year 10 of its model .

Earnings Estimates: Beating Consensus

Morgan Stanley's earnings forecasts significantly exceed Street consensus :

For context, Roche's own 2026 guidance calls for mid-single-digit sales growth and high-single-digit core EPS growth at constant exchange rates . In the first half of 2026, Roche delivered sales growth of 6% at CER and core EPS growth of 9% .

Other Pipeline Readouts Beyond Giredestrant

Morgan Stanley highlighted several pipeline catalysts from 2027 onward that support the upgrade :

• Ocrevus (ocrelizumab) — Subcutaneous formulation and potential label expansion into progressive multiple sclerosis .
• Vamikibart (anti-TL1A/anti-IL-6 antibody) — Phase II/III readouts in inflammatory bowel disease (IBD), with peak sales potential of CHF 0.5–1 billion .
• Prasinezumab — Phase IIb data in Parkinson's disease. While the 52-week Phase II PASADENA study missed its primary endpoint, five-year open-label extension data suggests potential sustained clinically meaningful effects on motor and function progression .
• CT-996 / oral GLP-1 — Early-stage obesity candidate that entered phase I development in partnership with Zealand Pharma (collaboration entered in 2025) .
• Divarasib — Phase III readouts in KRAS G12C-mutated non-small cell lung cancer (NSCLC) in combination with pembrolizumab .
• Afimkibart — Phase II data in rheumatoid arthritis .
• Fenebrutinib — Phase III readouts in multiple sclerosis (two RMS studies with primary completion dates in 2026, PPMS study expected to complete in 2027) .

Valuation Rationale

Morgan Stanley's price target upgrade from CHF 295 to CHF 410 (ADR target from $46 to $63) implies approximately 12% upside from the day-of-upgrade close .

While the published reports do not detail the bank's specific discounted cash flow (DCF) or sum-of-parts assumptions, the upgrade is explicitly driven by:

1. Revaluation of giredestrant's commercial opportunity — first-year sales of ~CHF 660 million versus the bank's prior, lower launch expectations .
2. Probability-weighted value of later-stage pipeline assets beyond giredestrant .

Morgan Stanley replaced AstraZeneca with Roche as its top pick, suggesting Roche now offers a more attractive risk/reward profile given the near-term FDA catalysts and the bank's view that the market was underappreciating the breadth of its pipeline . This marks a significant reversal from Morgan Stanley's stance in April and August 2025, when the bank maintained an Underweight rating on Roche and cut its price target to $46, citing FX headwinds and competitive concerns .

Upside Risk

If giredestrant reaches its peak sales potential — Roche has cited at least $14 billion in the early-stage breast cancer SERD market alone — further upward estimate revisions may occur . Morningstar raised its fair value estimate to CHF 381/USD 60 after increasing long-term giredestrant sales assumptions, noting it as the largest pipeline opportunity driving valuation .

Key Risks to Consider

• Biosimilar headwinds: Roche faces a loss-of-exclusivity impact of roughly CHF 600 million to CHF 1 billion in 2026 from biosimilars to Avastin, Herceptin, MabThera/Rituxan, Lucentis, and Actemra .
• Clinical trial risk: Prasinezumab failed its primary endpoint in the 52-week Phase II study, with only open-label extension data supporting potential efficacy .
• Commercial execution risk: While Morgan Stanley projects a faster launch, Jefferies projects just CHF 1.2 billion in peak yearly giredestrant sales — significantly below Roche's own estimates and the bank's assumptions .
• Forex headwinds: A strong Swiss franc continues to weigh on reported results (H1 2026 sales were +6% at CER but -2% in CHF) .

Giredestrant: The Core Catalyst

The upgrade is anchored on a dramatic revaluation of giredestrant, Roche's investigational oral selective estrogen receptor degrader (SERD) for ER+/HER2- breast cancer.

Expected FDA Decisions

Morgan Stanley analysts expect two U.S. approval decisions for giredestrant in late 2026 :

• lidERA study in adjuvant ER+/HER2-negative breast cancer — PDUFA date of November 30, 2026 .
• evERA study in post-CDK4/6 metastatic breast cancer — PDUFA date of December 18, 2026 .

The FDA accepted the New Drug Application (NDA) under Priority Review in June 2026 for the adjuvant indication . Giredestrant is the only oral SERD to show superior invasive disease-free survival in the adjuvant setting, marking the first significant endocrine therapy advance in over 20 years .

First-Year Sales Forecast

Morgan Stanley projects first-year U.S. giredestrant sales of roughly CHF 660 million (approximately $800 million), with upside to $1–1.2 billion depending on conversion of CDK4/6-intolerant patients . This reflects a faster launch trajectory and larger market capture than the bank previously modeled .

Peak Sales Potential

Roche has cited at least $14 billion in peak sales potential from the early-stage breast cancer SERD market alone, with a total addressable market of at least $20 billion for the drug class . Morningstar, which raised its fair value estimate for Roche to CHF 381 in April 2026, now assumes more than CHF 4 billion in giredestrant sales by year 10 of its model .

Earnings Estimates: Beating Consensus

Morgan Stanley's earnings forecasts significantly exceed Street consensus :

For context, Roche's own 2026 guidance calls for mid-single-digit sales growth and high-single-digit core EPS growth at constant exchange rates . In the first half of 2026, Roche delivered sales growth of 6% at CER and core EPS growth of 9% .

Other Pipeline Readouts Beyond Giredestrant

Morgan Stanley highlighted several pipeline catalysts from 2027 onward that support the upgrade :

• Ocrevus (ocrelizumab) — Subcutaneous formulation and potential label expansion into progressive multiple sclerosis .
• Vamikibart (anti-TL1A/anti-IL-6 antibody) — Phase II/III readouts in inflammatory bowel disease (IBD), with peak sales potential of CHF 0.5–1 billion .
• Prasinezumab — Phase IIb data in Parkinson's disease. While the 52-week Phase II PASADENA study missed its primary endpoint, five-year open-label extension data suggests potential sustained clinically meaningful effects on motor and function progression .
• CT-996 / oral GLP-1 — Early-stage obesity candidate that entered phase I development in partnership with Zealand Pharma (collaboration entered in 2025) .
• Divarasib — Phase III readouts in KRAS G12C-mutated non-small cell lung cancer (NSCLC) in combination with pembrolizumab .
• Afimkibart — Phase II data in rheumatoid arthritis .
• Fenebrutinib — Phase III readouts in multiple sclerosis (two RMS studies with primary completion dates in 2026, PPMS study expected to complete in 2027) .

Valuation Rationale

Morgan Stanley's price target upgrade from CHF 295 to CHF 410 (ADR target from $46 to $63) implies approximately 12% upside from the day-of-upgrade close .

While the published reports do not detail the bank's specific discounted cash flow (DCF) or sum-of-parts assumptions, the upgrade is explicitly driven by:

1. Revaluation of giredestrant's commercial opportunity — first-year sales of ~CHF 660 million versus the bank's prior, lower launch expectations .
2. Probability-weighted value of later-stage pipeline assets beyond giredestrant .

Morgan Stanley replaced AstraZeneca with Roche as its top pick, suggesting Roche now offers a more attractive risk/reward profile given the near-term FDA catalysts and the bank's view that the market was underappreciating the breadth of its pipeline . This marks a significant reversal from Morgan Stanley's stance in April and August 2025, when the bank maintained an Underweight rating on Roche and cut its price target to $46, citing FX headwinds and competitive concerns .

Upside Risk

If giredestrant reaches its peak sales potential — Roche has cited at least $14 billion in the early-stage breast cancer SERD market alone — further upward estimate revisions may occur . Morningstar raised its fair value estimate to CHF 381/USD 60 after increasing long-term giredestrant sales assumptions, noting it as the largest pipeline opportunity driving valuation .

Key Risks to Consider

• Biosimilar headwinds: Roche faces a loss-of-exclusivity impact of roughly CHF 600 million to CHF 1 billion in 2026 from biosimilars to Avastin, Herceptin, MabThera/Rituxan, Lucentis, and Actemra .
• Clinical trial risk: Prasinezumab failed its primary endpoint in the 52-week Phase II study, with only open-label extension data supporting potential efficacy .
• Commercial execution risk: While Morgan Stanley projects a faster launch, Jefferies projects just CHF 1.2 billion in peak yearly giredestrant sales — significantly below Roche's own estimates and the bank's assumptions .
• Forex headwinds: A strong Swiss franc continues to weigh on reported results (H1 2026 sales were +6% at CER but -2% in CHF) .